Bando, H
Skipping dose levels (e.g., jumping from 0.6 mg to 1.8 mg) should be avoided, as this significantly increases the risk of adverse events
Even though its unclear whether GLP-1 producers will market the medication to AUD patients in the future, Richards said this could become an "established medical practice once the safety and efficacy has been determined." For patients who struggle with AUD, Richards recommended they talk to their health care providers about available treatment
The solution is measuring your individual micronutrient status
GI side effects we see most (and what the science shows) The big four: nausea, early fullness (post-prandial satiety), reflux/belching, and altered bowel habits (constipation or diarrhea)
Keywords: incretins, type 2 diabetes, coagonists, GLP1, GIP, body weight Introduction Obesity and type 2 diabetes (T2D) remain epidemic problems